Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + fludarabine
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cyclophosphamide + fludarabine is a combination chemotherapy regimen primarily used in the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies. Cyclophosphamide is an alkylating agent that cross-links DNA strands, inhibiting DNA replication and leading to cell death. Fludarabine is a purine analog antimetabolite that inhibits DNA polymerase alpha, ribonucleotide reductase, and DNA primase—disrupting DNA synthesis and inducing apoptosis in both proliferating and non-proliferating cells. The combination exploits synergistic cytotoxicity to improve response rates compared to either drug alone[2][3][5][8]. This regimen may be referred to as "FC" or "FLU-CY" in clinical practice.
- Other names
- FCFLU-CY
02
Targets
DNA-directed primase/polymerase protein (PrimPol)DNAPOLA1 (DNA polymerase alpha)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on cyclophosphamide + fludarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + fludarabine.